FDA aims to speed biosimilar approvals to increase competition, but experts warn drug prices may not drop quickly.
David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback